BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO

- Oral presentation to reveal data from trial evaluating bemcentinib in relapsed mesothelioma -

- Trial-in-Progress poster to be presented regarding the BGBC016 1L STK11m NSCLC trial -


BERGEN, Norway, May 25, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting two abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 2-6, 2023.


An oral presentation will highlight the results of MIST3, an investigator led, multi-center Phase IIa study led by Professor Dean Fennell at the University of Leicester, UK that assessed the use of bemcentinib in combination with pembrolizumab in patients with relapsed mesothelioma.


A Trial-in-Progress poster will outline the plans for the ongoing BGBC016 Phase 1b/2a study evaluating bemcentinib in combination with pembrolizumab and chemotherapy in 1L STK11m NSCLC patients.


The abstracts will be available in Scientific Presentations on the Company’s website shortly after their presentations at the conference.


ASCO Abstract Details:


Oral Presentation

Title: Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy

Abstract Number: 8511

Abstract Session: Lung Cancer

Presenter: Matthew Krebs, Ph.D., FRCP, Christie Hospital, Manchester, UK

Date/Time: Monday 5th June, 11.30am – 1.00pm


Poster Presentation

Title: Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation

Abstract Number: TPS9154

Poster Number: 134b

Abstract Session: Lung Cancer – Non-Small Cell Metastatic

Presenter: Rajwanth Veluswamy, MD, MSCR, Mount Sinai, New York, NY

Date/Time: Sunday 4th June 8.00am-11.00am








Martin Olin CEO, BerGenBio ASA


Rune Skeie, CFO, BerGenBio ASA


Investor Relations


Graham Morrell


Media Relations


Jan Lilleby

+47 90 55 16 98


About BerGenBio ASA


BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.


BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more information, visit


Forward looking statements


This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties, and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.


This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.